greggles
I'll be back!
- Joined
- 28 July 2004
- Posts
- 4,501
- Reactions
- 4,616
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2018 Grünenthal employed around 4,900 people and achieved sales of € 1.3 bn.
Interesting perspective GB. Thanks for your thoughts.
Why do you think Grünenthal Group is throwing so much money at this? They appear to be a pretty reputable German outfit with a great deal of experience in the pain management field.
Surely they must see a lot of potential in MSB's Phase III trial for MPC-06-ID?
It doesn't address all forms of back pain, just inflammation which is normally treated by steroids.
The trial results so far are pretty good wouldn't you say?
Do you work in the area?
So if the studies Mesoblast quote are rubbish and this study iscorrect then the population that this product can treat is likely much smaller than Mesoblast hint at. The product may help where inflammation is the main problem but reducing disc deteriation is probably pointless.
So what is the main cause of lower back pain?
Overuse is easy to fix. Just stop. Next time use better posture with lifting, bending etc. Pain goes away immediately.Herniated disc seems to always mentioned.
Overuse is mentioned as common but pain is short term.
Fundamentals aside, $2 looks like a good entry point, if it trades there. Bottom of the flag.A raising at $2.
I sold 1/3 of my shares and planned to buy them back at $1.60. Price wouldn't drop, now I know why.
I must be getting old and cranky. I really dislike the convoluted announcements which are spruced up as marketing. Would have been much simpler to say:Raising succeeded at $2.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?